Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2Phase 3 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 3Sarcoma 3Head & Neck 2Gynecologic 2Dermatologic 2Plasma cell 1Genitourinary 1Gastrointestinal 1

Conditions

Uterine Cervical Dysplasia 1Ovarian Neoplasms 1

Interventions

Paclitaxel 233Carboplatin 217Bevacizumab 139Cisplatin 136pembrolizumab 89Gemcitabine 69olaparib 54Docetaxel 47Topotecan 44Radiotherapy 43liposomal doxorubicin 41Taxes 41niraparib 38Cyclophosphamide 36Doxorubicin 30Drug Therapy 29Letrozole 28Nivolumab 27Magnetic Resonance Spectroscopy 25Immunoglobulin G 25Disulfides 24Oxaliplatin 23Albumin-Bound Paclitaxel 23durvalumab 22apatinib 21Etoposide 21Brachytherapy 21lenvatinib 20camrelizumab 20Specimen Handling 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Nelfinavir × Gynecologic × Clear all
NCT06971744 2025-12-22

Autophagy Maintenance (AUTOMAIN)

Medical University of South Carolina

Phase 2 Recruiting
38 enrolled
Gynecologic

Ovarian Neoplasms

NCT01925378 2020-11-12

A Phase II Single-arm Intervention Trial of Nelfinavir in Patients With Grade 2/3 or 3 Cervical Intraepithelial Neoplasia

The University of Texas Health Science Center, Houston

Phase 2 Withdrawn
Gynecologic

Uterine Cervical Dysplasia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡